CN103911376B - CRISPR‑Cas9靶向敲除乙肝病毒cccDNA及其特异性sgRNA - Google Patents
CRISPR‑Cas9靶向敲除乙肝病毒cccDNA及其特异性sgRNA Download PDFInfo
- Publication number
- CN103911376B CN103911376B CN201410134461.8A CN201410134461A CN103911376B CN 103911376 B CN103911376 B CN 103911376B CN 201410134461 A CN201410134461 A CN 201410134461A CN 103911376 B CN103911376 B CN 103911376B
- Authority
- CN
- China
- Prior art keywords
- sgrna
- hbv
- plasmid
- seq
- pgl3
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108091027544 Subgenomic mRNA Proteins 0.000 title claims abstract description 139
- 108091036055 CccDNA Proteins 0.000 title claims abstract description 115
- 241000700721 Hepatitis B virus Species 0.000 title claims abstract description 50
- 238000010356 CRISPR-Cas9 genome editing Methods 0.000 title claims abstract description 18
- 238000000034 method Methods 0.000 claims abstract description 24
- 239000013612 plasmid Substances 0.000 claims description 136
- 108091034117 Oligonucleotide Proteins 0.000 claims description 54
- 102000004190 Enzymes Human genes 0.000 claims description 32
- 108090000790 Enzymes Proteins 0.000 claims description 32
- 238000000137 annealing Methods 0.000 claims description 29
- 238000012163 sequencing technique Methods 0.000 claims description 25
- 230000009471 action Effects 0.000 claims description 23
- 230000007850 degeneration Effects 0.000 claims description 22
- 108020004414 DNA Proteins 0.000 claims description 15
- 241000894006 Bacteria Species 0.000 claims description 13
- 230000015572 biosynthetic process Effects 0.000 claims description 10
- 238000010367 cloning Methods 0.000 claims description 9
- 238000003786 synthesis reaction Methods 0.000 claims description 9
- 238000001514 detection method Methods 0.000 claims description 8
- 230000000295 complement effect Effects 0.000 claims description 5
- 102100031673 Corneodesmosin Human genes 0.000 claims description 4
- 101710139375 Corneodesmosin Proteins 0.000 claims description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims 1
- 230000000844 anti-bacterial effect Effects 0.000 claims 1
- 239000003153 chemical reaction reagent Substances 0.000 claims 1
- 230000008685 targeting Effects 0.000 abstract description 42
- 238000002360 preparation method Methods 0.000 abstract description 14
- 238000003209 gene knockout Methods 0.000 abstract description 7
- 238000010353 genetic engineering Methods 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 91
- 239000000203 mixture Substances 0.000 description 42
- 238000006243 chemical reaction Methods 0.000 description 40
- 239000000047 product Substances 0.000 description 37
- 230000008859 change Effects 0.000 description 35
- 239000007788 liquid Substances 0.000 description 33
- 239000000427 antigen Substances 0.000 description 31
- 102000036639 antigens Human genes 0.000 description 31
- 108091007433 antigens Proteins 0.000 description 31
- 108091033409 CRISPR Proteins 0.000 description 25
- 238000001890 transfection Methods 0.000 description 23
- 239000013641 positive control Substances 0.000 description 18
- 238000011084 recovery Methods 0.000 description 18
- 238000005406 washing Methods 0.000 description 18
- 239000012097 Lipofectamine 2000 Substances 0.000 description 17
- 239000012096 transfection reagent Substances 0.000 description 17
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 16
- 108090000623 proteins and genes Proteins 0.000 description 16
- 238000012360 testing method Methods 0.000 description 16
- 238000005520 cutting process Methods 0.000 description 15
- 239000006228 supernatant Substances 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
- 230000000694 effects Effects 0.000 description 14
- 239000000872 buffer Substances 0.000 description 13
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 12
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 12
- 241000699670 Mus sp. Species 0.000 description 12
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 12
- 238000010363 gene targeting Methods 0.000 description 12
- 239000006166 lysate Substances 0.000 description 12
- 230000001404 mediated effect Effects 0.000 description 12
- 230000003020 moisturizing effect Effects 0.000 description 12
- 238000001556 precipitation Methods 0.000 description 12
- 238000011160 research Methods 0.000 description 12
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 12
- 230000009182 swimming Effects 0.000 description 10
- VOZKAJLKRJDJLL-UHFFFAOYSA-N 2,4-diaminotoluene Chemical compound CC1=CC=C(N)C=C1N VOZKAJLKRJDJLL-UHFFFAOYSA-N 0.000 description 9
- 238000009007 Diagnostic Kit Methods 0.000 description 9
- 238000004140 cleaning Methods 0.000 description 9
- 238000003776 cleavage reaction Methods 0.000 description 9
- 230000009514 concussion Effects 0.000 description 9
- 238000010790 dilution Methods 0.000 description 9
- 239000012895 dilution Substances 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- 238000002156 mixing Methods 0.000 description 9
- 239000008213 purified water Substances 0.000 description 9
- 230000007017 scission Effects 0.000 description 9
- 238000012408 PCR amplification Methods 0.000 description 8
- 241000700605 Viruses Species 0.000 description 7
- 238000000746 purification Methods 0.000 description 7
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 6
- 102000003960 Ligases Human genes 0.000 description 6
- 108090000364 Ligases Proteins 0.000 description 6
- 229930182555 Penicillin Natural products 0.000 description 6
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 6
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 6
- 238000004113 cell culture Methods 0.000 description 6
- 238000005119 centrifugation Methods 0.000 description 6
- YTRQFSDWAXHJCC-UHFFFAOYSA-N chloroform;phenol Chemical compound ClC(Cl)Cl.OC1=CC=CC=C1 YTRQFSDWAXHJCC-UHFFFAOYSA-N 0.000 description 6
- 238000005336 cracking Methods 0.000 description 6
- 239000012531 culture fluid Substances 0.000 description 6
- 238000013461 design Methods 0.000 description 6
- 238000001704 evaporation Methods 0.000 description 6
- 230000008020 evaporation Effects 0.000 description 6
- 229940049954 penicillin Drugs 0.000 description 6
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 229960005322 streptomycin Drugs 0.000 description 6
- 239000013598 vector Substances 0.000 description 6
- 239000003643 water by type Substances 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 5
- 208000002672 hepatitis B Diseases 0.000 description 5
- 239000003814 drug Substances 0.000 description 4
- 230000000977 initiatory effect Effects 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 239000000969 carrier Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 238000010354 CRISPR gene editing Methods 0.000 description 2
- 108020004638 Circular DNA Proteins 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 102100035102 E3 ubiquitin-protein ligase MYCBP2 Human genes 0.000 description 2
- 108700026244 Open Reading Frames Proteins 0.000 description 2
- 108091028113 Trans-activating crRNA Proteins 0.000 description 2
- 108010073062 Transcription Activator-Like Effectors Proteins 0.000 description 2
- 108020005202 Viral DNA Proteins 0.000 description 2
- 108010017070 Zinc Finger Nucleases Proteins 0.000 description 2
- 238000000246 agarose gel electrophoresis Methods 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 231100000221 frame shift mutation induction Toxicity 0.000 description 2
- 230000037433 frameshift Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 239000012160 loading buffer Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 230000029812 viral genome replication Effects 0.000 description 2
- 108091079001 CRISPR RNA Proteins 0.000 description 1
- 230000007018 DNA scission Effects 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 102100031780 Endonuclease Human genes 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 108020005004 Guide RNA Proteins 0.000 description 1
- 241000700739 Hepadnaviridae Species 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- -1 Nucleosides Nucleotides Nucleic Acids Chemical class 0.000 description 1
- 238000010459 TALEN Methods 0.000 description 1
- 108010043645 Transcription Activator-Like Effector Nucleases Proteins 0.000 description 1
- 108700005077 Viral Genes Proteins 0.000 description 1
- 101710086987 X protein Proteins 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000005289 controlled pore glass Substances 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000005782 double-strand break Effects 0.000 description 1
- 230000011559 double-strand break repair via nonhomologous end joining Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 239000003547 immunosorbent Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000006780 non-homologous end joining Effects 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 238000006384 oligomerization reaction Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 201000001862 viral hepatitis Diseases 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Abstract
Description
Claims (1)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410134461.8A CN103911376B (zh) | 2014-04-03 | 2014-04-03 | CRISPR‑Cas9靶向敲除乙肝病毒cccDNA及其特异性sgRNA |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410134461.8A CN103911376B (zh) | 2014-04-03 | 2014-04-03 | CRISPR‑Cas9靶向敲除乙肝病毒cccDNA及其特异性sgRNA |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103911376A CN103911376A (zh) | 2014-07-09 |
CN103911376B true CN103911376B (zh) | 2017-02-15 |
Family
ID=51037382
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410134461.8A Active CN103911376B (zh) | 2014-04-03 | 2014-04-03 | CRISPR‑Cas9靶向敲除乙肝病毒cccDNA及其特异性sgRNA |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103911376B (zh) |
Families Citing this family (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6261500B2 (ja) | 2011-07-22 | 2018-01-17 | プレジデント アンド フェローズ オブ ハーバード カレッジ | ヌクレアーゼ切断特異性の評価および改善 |
CA2898184A1 (en) | 2013-01-16 | 2014-07-24 | Emory University | Cas9-nucleic acid complexes and uses related thereto |
US20150044192A1 (en) | 2013-08-09 | 2015-02-12 | President And Fellows Of Harvard College | Methods for identifying a target site of a cas9 nuclease |
US9359599B2 (en) | 2013-08-22 | 2016-06-07 | President And Fellows Of Harvard College | Engineered transcription activator-like effector (TALE) domains and uses thereof |
US9526784B2 (en) | 2013-09-06 | 2016-12-27 | President And Fellows Of Harvard College | Delivery system for functional nucleases |
US9340799B2 (en) | 2013-09-06 | 2016-05-17 | President And Fellows Of Harvard College | MRNA-sensing switchable gRNAs |
US9388430B2 (en) | 2013-09-06 | 2016-07-12 | President And Fellows Of Harvard College | Cas9-recombinase fusion proteins and uses thereof |
LT3066201T (lt) | 2013-11-07 | 2018-08-10 | Editas Medicine, Inc. | Su crispr susiję būdai ir kompozicijos su valdančiomis grnr |
US9840699B2 (en) | 2013-12-12 | 2017-12-12 | President And Fellows Of Harvard College | Methods for nucleic acid editing |
WO2015184268A1 (en) | 2014-05-30 | 2015-12-03 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions and methods of delivering treatments for latent viral infections |
EP2966170A1 (en) * | 2014-07-10 | 2016-01-13 | Heinrich-Pette-Institut Leibniz-Institut für experimentelle Virologie-Stiftung bürgerlichen Rechts - | HBV inactivation |
WO2016022363A2 (en) | 2014-07-30 | 2016-02-11 | President And Fellows Of Harvard College | Cas9 proteins including ligand-dependent inteins |
CN104388456A (zh) * | 2014-10-31 | 2015-03-04 | 东华大学 | 一种同时表达两条sgRNA的载体的构建方法 |
CN104498493B (zh) * | 2014-12-30 | 2017-12-26 | 武汉大学 | CRISPR/Cas9特异性敲除乙型肝炎病毒的方法以及用于特异性靶向HBV DNA的gRNA |
CN104651399B (zh) * | 2014-12-31 | 2018-11-16 | 广西大学 | 一种利用CRISPR/Cas系统在猪胚胎细胞中实现基因敲除的方法 |
CN104711257B (zh) * | 2015-02-09 | 2017-11-03 | 鲁凤民 | 用于乙型肝炎病毒感染治疗的导向rna靶点 |
CN104673816A (zh) * | 2015-03-05 | 2015-06-03 | 广东医学院 | 一种pCr-NHEJ载体及其构建方法及其用于细菌基因定点敲除的应用 |
CN106167810A (zh) * | 2015-04-03 | 2016-11-30 | 内蒙古中科正标生物科技有限责任公司 | 基于CRISPR/Cas9技术的单子叶植物基因敲除载体及其应用 |
CN104805118A (zh) * | 2015-04-22 | 2015-07-29 | 扬州大学 | 一种苏禽黄鸡胚胎干细胞特定基因进行靶向敲除方法 |
US20190225955A1 (en) | 2015-10-23 | 2019-07-25 | President And Fellows Of Harvard College | Evolved cas9 proteins for gene editing |
CN105647922A (zh) * | 2016-01-11 | 2016-06-08 | 中国人民解放军疾病预防控制所 | 基于一种新gRNA序列的CRISPR-Cas9系统在制备乙肝治疗药物中的应用 |
CN105561342A (zh) * | 2016-01-27 | 2016-05-11 | 苏州佰通生物科技有限公司 | 一种治疗乙肝的基因药物及其制备方法 |
CN105821039B (zh) * | 2016-03-09 | 2020-02-07 | 李旭 | 联合免疫基因抑制HBV复制的特异性sgRNA、表达载体及其应用 |
CN105821040B (zh) * | 2016-03-09 | 2018-12-14 | 李旭 | 联合免疫基因抑制高危型HPV表达的sgRNA、基因敲除载体及其应用 |
KR102547316B1 (ko) | 2016-08-03 | 2023-06-23 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 아데노신 핵염기 편집제 및 그의 용도 |
AU2017308889B2 (en) | 2016-08-09 | 2023-11-09 | President And Fellows Of Harvard College | Programmable Cas9-recombinase fusion proteins and uses thereof |
US11542509B2 (en) | 2016-08-24 | 2023-01-03 | President And Fellows Of Harvard College | Incorporation of unnatural amino acids into proteins using base editing |
KR20240007715A (ko) | 2016-10-14 | 2024-01-16 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 핵염기 에디터의 aav 전달 |
CN106729753A (zh) * | 2016-12-16 | 2017-05-31 | 谭旭 | 抗乙型肝炎病毒的递送系统和生物制剂 |
US10745677B2 (en) | 2016-12-23 | 2020-08-18 | President And Fellows Of Harvard College | Editing of CCR5 receptor gene to protect against HIV infection |
AU2017385611B2 (en) * | 2016-12-29 | 2023-11-02 | Johann Wolfgang Goethe-Universität Frankfurt am Main | Method for generating higher order genome editing libraries |
CN106701763B (zh) * | 2016-12-30 | 2019-07-19 | 重庆高圣生物医药有限责任公司 | CRISPR/Cas9靶向敲除人乙肝病毒P基因及其特异性gRNA |
US11898179B2 (en) | 2017-03-09 | 2024-02-13 | President And Fellows Of Harvard College | Suppression of pain by gene editing |
EP3592777A1 (en) | 2017-03-10 | 2020-01-15 | President and Fellows of Harvard College | Cytosine to guanine base editor |
US11268082B2 (en) | 2017-03-23 | 2022-03-08 | President And Fellows Of Harvard College | Nucleobase editors comprising nucleic acid programmable DNA binding proteins |
US11560566B2 (en) | 2017-05-12 | 2023-01-24 | President And Fellows Of Harvard College | Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation |
WO2019023680A1 (en) | 2017-07-28 | 2019-01-31 | President And Fellows Of Harvard College | METHODS AND COMPOSITIONS FOR EVOLUTION OF BASIC EDITORS USING PHAGE-ASSISTED CONTINUOUS EVOLUTION (PACE) |
MX2020001178A (es) * | 2017-07-31 | 2020-09-25 | Regeneron Pharma | Celulas madre embrionarias de raton transgenico con cas y ratones y usos de los mismos. |
WO2019139645A2 (en) | 2017-08-30 | 2019-07-18 | President And Fellows Of Harvard College | High efficiency base editors comprising gam |
US11795443B2 (en) | 2017-10-16 | 2023-10-24 | The Broad Institute, Inc. | Uses of adenosine base editors |
CA3130488A1 (en) | 2019-03-19 | 2020-09-24 | David R. Liu | Methods and compositions for editing nucleotide sequences |
GB2614813A (en) | 2020-05-08 | 2023-07-19 | Harvard College | Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence |
CN113249384A (zh) * | 2021-04-27 | 2021-08-13 | 重庆医科大学 | 可靶向编辑HBV cccDNA的特异sgRNA序列及其应用 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103668472A (zh) * | 2013-12-31 | 2014-03-26 | 北京大学 | 利用CRISPR/Cas9系统构建真核基因敲除文库的方法 |
-
2014
- 2014-04-03 CN CN201410134461.8A patent/CN103911376B/zh active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103668472A (zh) * | 2013-12-31 | 2014-03-26 | 北京大学 | 利用CRISPR/Cas9系统构建真核基因敲除文库的方法 |
Non-Patent Citations (2)
Title |
---|
RNA-Guided Human Genome Engineering via Cas9;Prashant Mali等;《Science》;20130215;第823页摘要,第823页中栏第5行-右栏第2行,第824页图1A,第825页图2,附加材料中的"材料与方法"部分 * |
siRNA抑制乙型肝炎病毒在HepG2.2.15细胞中的复制与表达;边中启等;《中华医学杂志》;20090210;第347页摘要,第348页左栏第一段 * |
Also Published As
Publication number | Publication date |
---|---|
CN103911376A (zh) | 2014-07-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103911376B (zh) | CRISPR‑Cas9靶向敲除乙肝病毒cccDNA及其特异性sgRNA | |
CN103820441B (zh) | CRISPR‑Cas9特异性敲除人CTLA4基因的方法以及用于特异性靶向CTLA4基因的sgRNA | |
CN106222177B (zh) | 一种靶向人STAT6的CRISPR-Cas9系统及其用于治疗过敏性疾病的应用 | |
CN103923911B (zh) | CRISPR-Cas9特异性敲除人CCR5基因的方法以及用于特异性靶向CCR5基因的sgRNA | |
US20200172935A1 (en) | Modified cpf1 mrna, modified guide rna, and uses thereof | |
US20220033858A1 (en) | Crispr oligoncleotides and gene editing | |
Kan et al. | Mechanisms of precise genome editing using oligonucleotide donors | |
CN107083392B (zh) | 一种CRISPR/Cpf1基因编辑系统及其在分枝杆菌中的应用 | |
CN105886498A (zh) | CRISPR-Cas9特异性敲除人PCSK9基因的方法以及用于特异性靶向PCSK9基因的sgRNA | |
Damgaard et al. | RNA interactions in the 5′ region of the HIV-1 genome | |
CN105518138B (zh) | CRISPR-Cas9特异性敲除猪GFRA1基因的方法及用于特异性靶向GFRA1基因的sgRNA | |
Cuomo et al. | DNA sequence and structure requirements for cleavage of V (D) J recombination signal sequences | |
WO2017190664A1 (zh) | 化学合成的crRNA和修饰crRNA在CRISPR/Cpf1基因编辑系统中的应用 | |
Jacquenet et al. | Conserved stem–loop structures in the HIV-1 RNA region containing the A3 3′ splice site and its cis-regulatory element: possible involvement in RNA splicing | |
JP7099724B2 (ja) | 規定された配列および長さのdna1本鎖分子の拡大可能な生物工学的生成 | |
Lin et al. | A single amino acid in the reverse transcriptase domain of hepatitis B virus affects virus replication efficiency | |
CN106414740A (zh) | CRISPR‑Cas9特异性敲除猪SLA‑3基因的方法及用于特异性靶向SLA‑3基因的sgRNA | |
US20210147915A1 (en) | Crispr/cas and transposase based amplification compositions, systems and methods | |
CN105602972B (zh) | 基于CRISPR-Cas9体外改造腺病毒载体的方法 | |
US20190241911A1 (en) | Engineered guide rna and uses thereof | |
Hou et al. | Assembly of long DNA sequences using a new synthetic Escherichia coli-yeast shuttle vector | |
US20190032122A1 (en) | Indel detection by amplicon analysis | |
Ly et al. | Moloney murine sarcoma virus genomic RNAs dimerize via a two-step process: a concentration-dependent kissing-loop interaction is driven by initial contact between consecutive guanines | |
WO2022098885A1 (en) | Precise genome deletion and replacement method based on prime editing | |
CN103540587A (zh) | 靶向整合外源DNA序列到大鼠和小鼠Rosa26位点的方法及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20160114 Address after: 201210 Lane 678 Hua Tuo Road, Shanghai, Pudong New Area Applicant after: Huang Xingxu Address before: 210093 Hankou Road, Jiangsu, China, No. 22, No. Applicant before: Nanjing University |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20160225 Address after: 201203 Shanghai city Chinese (Shanghai) free trade zone 351 GuoShouJing Road No. 2 building A679-05 room Applicant after: HUANG XINGXU Address before: 201210 Lane 678 Hua Tuo Road, Shanghai, Pudong New Area Applicant before: Huang Xingxu |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20161027 Address after: 200120, room 1, No. 323, Lane 601, little wooden bridge road, Shanghai, Xuhui District Applicant after: Huang Xingxu Address before: 201203 Shanghai city Chinese (Shanghai) free trade zone 351 GuoShouJing Road No. 2 building A679-05 room Applicant before: HUANG XINGXU |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20180620 Address after: 510660 room 227, A 227, Shi Huan Road, Tianhe District, Guangzhou, Guangdong. Patentee after: Esoteric Biotechnology (Guangzhou) Co., Ltd. Address before: 200120 601, 1 Lane 323 lane, Xiao Mu Qiao Road, Xuhui District, Shanghai. Patentee before: Huang Xingxu |
|
TR01 | Transfer of patent right |